These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1240 related articles for article (PubMed ID: 25208879)

  • 1. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
    Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH
    Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
    Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
    Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
    Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
    Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Classification Models for Triple Negative Breast Cancer Subtype Using Machine Learning.
    Bissanum R; Chaichulee S; Kamolphiwong R; Navakanitworakul R; Kanokwiroon K
    J Pers Med; 2021 Sep; 11(9):. PubMed ID: 34575658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity.
    Ding YC; Steele L; Warden C; Wilczynski S; Mortimer J; Yuan Y; Neuhausen SL
    Oncotarget; 2019 Jan; 10(2):198-208. PubMed ID: 30719214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.
    Hu H; Tong K; Tsang JY; Ko CW; Tam F; Loong TC; Tse GM
    ESMO Open; 2024 Apr; 9(4):102993. PubMed ID: 38613910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance.
    Leeha M; Kanokwiroon K; Laohawiriyakamol S; Thongsuksai P
    Pathol Oncol Res; 2023; 29():1611162. PubMed ID: 37274773
    [No Abstract]   [Full Text] [Related]  

  • 9. Triple-Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant Chemotherapy.
    Paula B; Crocamo S; de Sousa CAM; Valverde P; Rezende F; Abdelhay E
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More Than Meets the Eye: A Case of Breast Cancer Switching from Being Luminal-Androgen-Receptor-Positive to Being Hormone-Receptor-Positive.
    Martorana F; Di Grazia G; Rosano GN; Vecchio GM; Conti C; Nucera S; Magro G; Vigneri P
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
    Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasonographic appearance of triple-negative invasive breast carcinoma is associated with novel molecular subtypes based on transcriptomic analysis.
    Li JW; Li N; Jiang YZ; Liu YR; Shi ZT; Chang C; Shao ZM
    Ann Transl Med; 2020 Apr; 8(7):435. PubMed ID: 32395479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
    Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.
    Jézéquel P; Lasla H; Gouraud W; Basseville A; Michel B; Frenel JS; Juin PP; Ben Azzouz F; Campone M
    Breast Cancer; 2024 May; ():. PubMed ID: 38777987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles.
    Akhouayri L; Ostano P; Mello-Grand M; Gregnanin I; Crivelli F; Laurora S; Liscia D; Leone F; Santoro A; Mulè A; Guarino D; Maggiore C; Carlino A; Magno S; Scatolini M; Di Leone A; Masetti R; Chiorino G
    Hum Genomics; 2022 Dec; 16(1):70. PubMed ID: 36536459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers.
    Wang L; Lang GT; Xue MZ; Yang L; Chen L; Yao L; Li XG; Wang P; Hu X; Shao ZM
    Theranostics; 2020; 10(23):10531-10547. PubMed ID: 32929364
    [No Abstract]   [Full Text] [Related]  

  • 18. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
    Xiao Y; Ma D; Yang YS; Yang F; Ding JH; Gong Y; Jiang L; Ge LP; Wu SY; Yu Q; Zhang Q; Bertucci F; Sun Q; Hu X; Li DQ; Shao ZM; Jiang YZ
    Cell Res; 2022 May; 32(5):477-490. PubMed ID: 35105939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
    Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
    Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
    BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.